Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1985 1
1992 1
1993 1
2005 1
2006 2
2007 2
2008 1
2009 1
2010 4
2011 3
2012 3
2013 5
2014 15
2015 14
2016 12
2017 7
2018 8
2019 6
2020 9
2021 7
2022 8
2023 7

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Huang D, Waltl EE, Winderlich M, Kurukulasuriya NC, Ambarkhane S, Hess G, Salles G. Nowakowski GS, et al. Among authors: mondello p. Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648. Clin Cancer Res. 2022. PMID: 35674661 Free PMC article.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: mondello p. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12. Ann Hematol. 2023. PMID: 37171597 Free PMC article.
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse.
Bobillo S, Joffe E, Sermer D, Mondello P, Ghione P, Caron PC, Hamilton A, Hamlin PA, Horwitz SM, Kumar A, Matasar MJ, Batlevi CL, Moskowitz A, Noy A, Owens CN, Palomba ML, Straus D, von Keudell G, Dogan A, Zelenetz AD, Seshan VE, Younes A. Bobillo S, et al. Among authors: mondello p. Blood Cancer J. 2021 Jun 16;11(6):113. doi: 10.1038/s41408-021-00506-3. Blood Cancer J. 2021. PMID: 34135307 Free PMC article.
Insights into the tumor microenvironment of B cell lymphoma.
Ng WL, Ansell SM, Mondello P. Ng WL, et al. Among authors: mondello p. J Exp Clin Cancer Res. 2022 Dec 29;41(1):362. doi: 10.1186/s13046-022-02579-9. J Exp Clin Cancer Res. 2022. PMID: 36578079 Free PMC article. Review.
The heart in Anderson-Fabry disease.
Sestito S, Roppa K, Parisi F, Moricca MT, Pensabene L, Chimenz R, Ceravolo MD, Cucinotta U, Ceravolo G, Calabrò MP, Cuppari C, Mondello P, Musolino D, Tallarico V, Concolino D. Sestito S, et al. Among authors: mondello p. J Biol Regul Homeost Agents. 2020 Jul-Aug;34(4 Suppl. 2):63-69. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. J Biol Regul Homeost Agents. 2020. PMID: 33000603 No abstract available.
Congenital heart disease in Down Syndrome.
Gramaglia SMC, Cuppari C, Salpietro C, Ceravolo A, Cutrupi MC, Concolino D, De Sarro R, Amatruda M, Mondello P, Ceravolo G, Calabrò MP, Gitto E. Gramaglia SMC, et al. Among authors: mondello p. J Biol Regul Homeost Agents. 2020 Jul-Aug;34(4 Suppl. 2):31-35. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. J Biol Regul Homeost Agents. 2020. PMID: 33000597 No abstract available.
105 results